FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4367307535> ?p ?o ?g. }

• W4367307535 endingPage "1330" @default.
• W4367307535 startingPage "1321" @default.
• W4367307535 abstract "Background: The present study aimed at investigating the feasibility and safety of induction chemotherapy followed by definitive chemoradiation (dCRT) in patients with locally advanced cervical cancer. Materials and Methods: In this single-arm clinical trial, patients with cervical cancer (stages IB3-IVA) received a median four cycles of induction chemotherapy (paclitaxel and carboplatin, every three weeks) followed by dCRT (which consisted of the whole pelvis at the dose of 45-50 Gy along with weekly cisplatin (40 mg/m2) followed by intracavitary brachytherapy at the total dose of 80-90 Gy). Primary end point was local control at three months, which was assessed by gynecologic examination and pelvic MRI. The secondary outcome of the study was treatment-related toxicity. Results: Seventy-four patients with the mean age of 51.6 ± 9.5 years were included. The most frequent (51.4%) disease stage was IIB. Complete and partial clinical responses were observed in 60.8% and 14.9% of patients, respectively. The frequency of progressive disease and stable disease were 14.9% and 9.5%, respectively. Grade II and III neutropenia (during neoadjuvant chemotherapy were 13.5% and 2.7%, respectively; these figures during chemoradiation were 29.7% and 13.5%, respectively. A treatment interruption was observed for 60.8% (45 cases) of patients during chemoradiation and 31.1% during induction chemotherapy. Discussion and conclusion: Induction chemotherapy followed by chemoradiation is feasible in patients with locally advanced cervical cancer; however, the toxicity should be managed properly to avoid delayed e treatment. More than three quarters of the patients achieved complete or partial clinical response within a three-month follow-up." @default.
• W4367307535 created "2023-04-29" @default.
• W4367307535 creator A5003588946 @default.
• W4367307535 creator A5018995744 @default.
• W4367307535 creator A5034365402 @default.
• W4367307535 creator A5042762460 @default.
• W4367307535 creator A5054656601 @default.
• W4367307535 creator A5074523985 @default.
• W4367307535 creator A5078424169 @default.
• W4367307535 creator A5078531864 @default.
• W4367307535 creator A5079101907 @default.
• W4367307535 creator A5083277481 @default.
• W4367307535 creator A5083487083 @default.
• W4367307535 creator A5091245364 @default.
• W4367307535 date "2023-04-01" @default.
• W4367307535 modified "2023-10-01" @default.
• W4367307535 title "The Feasibility and Safety of Induction Chemotherapy Followed by Definitive Chemoradiation in Patients with Locally Advanced Cervical Cancer: A Single-Arm Phase II Clinical Trial" @default.
• W4367307535 cites W1935824237 @default.
• W4367307535 cites W2045598378 @default.
• W4367307535 cites W2094983511 @default.
• W4367307535 cites W2097972415 @default.
• W4367307535 cites W2104360894 @default.
• W4367307535 cites W2106787323 @default.
• W4367307535 cites W2138550445 @default.
• W4367307535 cites W2157719711 @default.
• W4367307535 cites W2170091237 @default.
• W4367307535 cites W2190870061 @default.
• W4367307535 cites W2314753133 @default.
• W4367307535 cites W2324392028 @default.
• W4367307535 cites W2328935341 @default.
• W4367307535 cites W2565179808 @default.
• W4367307535 cites W2598381289 @default.
• W4367307535 cites W2734796223 @default.
• W4367307535 cites W2755837576 @default.
• W4367307535 cites W2809409170 @default.
• W4367307535 cites W2898641526 @default.
• W4367307535 cites W2971323891 @default.
• W4367307535 cites W3154435002 @default.
• W4367307535 cites W3175665726 @default.
• W4367307535 cites W3209804014 @default.
• W4367307535 cites W4221059725 @default.
• W4367307535 cites W4298106286 @default.
• W4367307535 doi "https://doi.org/10.31557/apjcp.2023.24.4.1321" @default.
• W4367307535 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37116155" @default.
• W4367307535 hasPublicationYear "2023" @default.
• W4367307535 type Work @default.
• W4367307535 citedByCount "0" @default.
• W4367307535 crossrefType "journal-article" @default.
• W4367307535 hasAuthorship W4367307535A5003588946 @default.
• W4367307535 hasAuthorship W4367307535A5018995744 @default.
• W4367307535 hasAuthorship W4367307535A5034365402 @default.
• W4367307535 hasAuthorship W4367307535A5042762460 @default.
• W4367307535 hasAuthorship W4367307535A5054656601 @default.
• W4367307535 hasAuthorship W4367307535A5074523985 @default.
• W4367307535 hasAuthorship W4367307535A5078424169 @default.
• W4367307535 hasAuthorship W4367307535A5078531864 @default.
• W4367307535 hasAuthorship W4367307535A5079101907 @default.
• W4367307535 hasAuthorship W4367307535A5083277481 @default.
• W4367307535 hasAuthorship W4367307535A5083487083 @default.
• W4367307535 hasAuthorship W4367307535A5091245364 @default.
• W4367307535 hasBestOaLocation W43673075351 @default.
• W4367307535 hasConcept C121608353 @default.
• W4367307535 hasConcept C126322002 @default.
• W4367307535 hasConcept C141071460 @default.
• W4367307535 hasConcept C143998085 @default.
• W4367307535 hasConcept C146357865 @default.
• W4367307535 hasConcept C151730666 @default.
• W4367307535 hasConcept C203092338 @default.
• W4367307535 hasConcept C2776611710 @default.
• W4367307535 hasConcept C2776694085 @default.
• W4367307535 hasConcept C2777063308 @default.
• W4367307535 hasConcept C2777416452 @default.
• W4367307535 hasConcept C2778220009 @default.
• W4367307535 hasConcept C2778239845 @default.
• W4367307535 hasConcept C2778424827 @default.
• W4367307535 hasConcept C2778822529 @default.
• W4367307535 hasConcept C2781451048 @default.
• W4367307535 hasConcept C31760486 @default.
• W4367307535 hasConcept C509974204 @default.
• W4367307535 hasConcept C535046627 @default.
• W4367307535 hasConcept C71924100 @default.
• W4367307535 hasConcept C86803240 @default.
• W4367307535 hasConceptScore W4367307535C121608353 @default.
• W4367307535 hasConceptScore W4367307535C126322002 @default.
• W4367307535 hasConceptScore W4367307535C141071460 @default.
• W4367307535 hasConceptScore W4367307535C143998085 @default.
• W4367307535 hasConceptScore W4367307535C146357865 @default.
• W4367307535 hasConceptScore W4367307535C151730666 @default.
• W4367307535 hasConceptScore W4367307535C203092338 @default.
• W4367307535 hasConceptScore W4367307535C2776611710 @default.
• W4367307535 hasConceptScore W4367307535C2776694085 @default.
• W4367307535 hasConceptScore W4367307535C2777063308 @default.
• W4367307535 hasConceptScore W4367307535C2777416452 @default.
• W4367307535 hasConceptScore W4367307535C2778220009 @default.
• W4367307535 hasConceptScore W4367307535C2778239845 @default.
• W4367307535 hasConceptScore W4367307535C2778424827 @default.
• W4367307535 hasConceptScore W4367307535C2778822529 @default.
• W4367307535 hasConceptScore W4367307535C2781451048 @default.

• next